

Table 1. Detection of antiviral drug-resistant viruses in Japan during the 2019/2020 influenza season

as of August 18, 2021

	A(H1N1)pdm09						A(H3N2)						B				
	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir
Resistant (%)	1 ^a (0.11%)	48 ^b (1.7%)	48 ^b (1.7%)	0	0	92 (100%)	0	0	0	0	0	37 (100%)	0	0	0	0	0
Number of viruses tested	949	2,750	2,750	384	384	92	89	90	90	90	90	37	160	149	149	149	149
Number of viruses reported	5,175						133						745				

Baloxavir was examined by focus reduction assay and/or PA sequencing.

NA inhibitors were examined by fluorescence-based NA-Fluor assay, chemiluminescence-based NA-XTD assay, real time RT-PCR allelic discrimination and/or NA sequencing.

Amantadine was examined by M2 sequencing.

^a Patients without treatment 1

^b Patients without treatment 33